Novartis | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 36.4B 2.35B 2025-03
Alcon AG USD 2.25B 32M 2025-03
Almirall EUR 298.52M 36.18M 2025-06
Amgen USD 20.48B 2.53B 2025-06
AstraZeneca USD 33.54B 4.41B 2025-06
Autolus Therapeutics Ltd 66.61M 5.87M 2025-03
Bayer EUR 27.96B 993M 2025-03
Biogen USD 3.18B 2.11B 2025-06
Bristol-Myers Squibb USD 27.53B 3.46B 2025-06
Eli Lilly USD 39.02B 8.95B 2025-06
Fresenius EUR 8.33B 2.24B 2025-03
Fresenius Medical Care EUR 5.45B 213.2M 2025-03
Galapagos EUR 402.95M 34.09M 2025-06
Genmab DKK 756M 4.55B 2025-03
Gilead Sciences USD 11.19B 1.15B 2025-06
GlaxoSmithKline GBP 20.38B 453M 2025-06
GRIFOLS EUR 1.99B 180.07M 2025-06
Hikma Pharmaceutical USD 1.98B 598M 2024-12
J&J USD 56.9B 6.58B 2025-03
Lonza CHF 3.58B 970M 2024-12
Merck EUR 9.86B 357M 2025-06
Merck USD 26.04B 863M 2025-06
Novartis USD 31.71B 95M 2025-06
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 207.52B 28.6B 2025-06
Orion EUR 540.8M 254.6M 2025-06
Pfizer USD 37.73B 1.27B 2025-06
Philips EUR 7.2B 445M 2025-06
Recordati EUR 1.07B 82.43M 2025-06
Regeneron Pharmaceuticals USD 3.67B 100.4M 2025-06
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 29.06B 3.16B 2025-06
UCB EUR 3.53B 731M 2024-12


Novartis Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.